MEIS2 expression is highly downregulated in thyroid cancer patients, as demonstrated by Wen et al. (49) suggesting that MEIS2 may be a target for early diagnosis and targeted therapy in these individuals. Here, MEIS2 is linked to thyroid gland carcinoma.